Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
We wanted to determine the efficacy and the safety of caspofungin acetate (CANCIDAS®) in the
treatment of invader fungal infection (IFI) specifically, Invasive Candidiasis (CI) in adults
patients without neutropenia and Invasive Aspergillosis (AI) in adults patients who are
refractory to or intolerant of other therapies (i.e., amphotericin B, lipid formulations of
amphotericin B, and/or itraconazole).